Ulcerative colitis (UC) is a disease that affects colon or large intestine and results in inflammation of the colon and development of ulcers on intestinal linings. The disease is a result of improper functioning of immune system. As a repercussion, white blood cells (WBCs) reach the lining of large intestine, resulting in its inflammation. Signs of the disease usually are cramps in abdominal region, bloody stools, lose or urgent bowel movements, and others. The disease is non-contagious. Moreover, family history is a significant risk factor for the disease.
Treatment options for UC include infliximab, tofacitinib, aminosalicylate, corticosteroid, immunosuppressant, and ciclosporin for the reduction of inflammation. Surgery is the ultimate solution for the disease in extreme cases. The diagnosis of the disease is possible through physical examination and lab tests.
It has been observed that many pharmaceutical companies are developing new and improved technologies for the development of UC therapeutics. For instance, Seres Therapeutics Inc. have developed microbiome technology to design specific therapies for particular diseases. For instance, the company developed Ecobiotic drugs for the treatment of UC.
Pre-Purchase Inquiry at: https://www.pharmaproff.com/enquiry/1252
Xeljanz, Simponi, Remicade, and Entyvio are some of the approved drugs for the treatment of UC. These drugs hold significant share in the global UC therapeutics market. Therefore, with the emergence of late- and mid-stage pipeline products in the market, the overall UC therapeutics market is expected to grow significantly in the upcoming years.
Some of the key players involved in the development of UC therapeutics are Pfizer Inc., Takeda Pharmaceutical Company Limited, Seres Therapeutics Inc., Janssen Biotech Inc., Receptos Inc., EA Pharma Co. Ltd., Celgene Corporation, and InDex Pharmaceuticals AB.
Treatment options for UC include infliximab, tofacitinib, aminosalicylate, corticosteroid, immunosuppressant, and ciclosporin for the reduction of inflammation. Surgery is the ultimate solution for the disease in extreme cases. The diagnosis of the disease is possible through physical examination and lab tests.
Pre-Purchase Inquiry at: https://www.pharmaproff.com/enquiry/1252
Xeljanz, Simponi, Remicade, and Entyvio are some of the approved drugs for the treatment of UC. These drugs hold significant share in the global UC therapeutics market. Therefore, with the emergence of late- and mid-stage pipeline products in the market, the overall UC therapeutics market is expected to grow significantly in the upcoming years.
Some of the key players involved in the development of UC therapeutics are Pfizer Inc., Takeda Pharmaceutical Company Limited, Seres Therapeutics Inc., Janssen Biotech Inc., Receptos Inc., EA Pharma Co. Ltd., Celgene Corporation, and InDex Pharmaceuticals AB.
0 Comments